对Felix Melchior、Andreas Pircher和Isabel Heidegger给编辑的信的答复:Johann S. de Bono,孟He, Chen Shi等。在IPATential150期临床试验中,接受Ipatasertib和Abiraterone的患者的最终总生存期和与临床结果相关的分子数据。Urol欧元。在出版社。https://doi.org/10.1016/j.eururo.2024.12.015
Christopher Sweeney , Meng He , Matthew Wongchenko , Roberta Ferraldeschi , Johann S. de Bono
{"title":"对Felix Melchior、Andreas Pircher和Isabel Heidegger给编辑的信的答复:Johann S. de Bono,孟He, Chen Shi等。在IPATential150期临床试验中,接受Ipatasertib和Abiraterone的患者的最终总生存期和与临床结果相关的分子数据。Urol欧元。在出版社。https://doi.org/10.1016/j.eururo.2024.12.015","authors":"Christopher Sweeney , Meng He , Matthew Wongchenko , Roberta Ferraldeschi , Johann S. de Bono","doi":"10.1016/j.eururo.2025.03.020","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"87 6","pages":"Pages e115-e116"},"PeriodicalIF":25.3000,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Reply to Felix Melchior, Andreas Pircher, and Isabel Heidegger’s Letter to the Editor re: Johann S. de Bono, Meng He, Chen Shi, et al. Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial. Eur Urol. 2025;87:468–75\",\"authors\":\"Christopher Sweeney , Meng He , Matthew Wongchenko , Roberta Ferraldeschi , Johann S. de Bono\",\"doi\":\"10.1016/j.eururo.2025.03.020\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":12223,\"journal\":{\"name\":\"European urology\",\"volume\":\"87 6\",\"pages\":\"Pages e115-e116\"},\"PeriodicalIF\":25.3000,\"publicationDate\":\"2025-04-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European urology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0302283825001939\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European urology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0302283825001939","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
Reply to Felix Melchior, Andreas Pircher, and Isabel Heidegger’s Letter to the Editor re: Johann S. de Bono, Meng He, Chen Shi, et al. Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial. Eur Urol. 2025;87:468–75
期刊介绍:
European Urology is a peer-reviewed journal that publishes original articles and reviews on a broad spectrum of urological issues. Covering topics such as oncology, impotence, infertility, pediatrics, lithiasis and endourology, the journal also highlights recent advances in techniques, instrumentation, surgery, and pediatric urology. This comprehensive approach provides readers with an in-depth guide to international developments in urology.